Lumida
/LUNG
⌘K
Pulmonx Corp

Pulmonx Corp

LUNG
$1.40USD↓-3.45%-0.05 today

MARKET CAP

59.1M

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$1 – $1

52W RANGE

$1
$4

AI Summary

Stalk
TrimMedium

In a Stage 4 decline featuring persistent lower highs and lower lows, the medium-term bias remains bearish under declining EMAs and distribution volume. Short-term timing is neutral as price tightly tracks flat EMAs and is oversold, suggesting risk of a bounce. Therefore, execution is deferred with a Trim approach, awaiting stalled rallies into structural resistance.

  • ↑Maintains 2026 revenue guidance of $90–92M, targeting sequential quarterly improvement
  • ↑Aims for 70,000+ first-time patient engagements in 2025 via DTP campaigns
  • ↓Q1 revenue down 9% YoY to $20.6M; U.S. fell 7%, international down 12%
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Pulmonx Corporation (NASDAQ: PULM) is a leading company in the medical devices sector, specializing in innovative solutions for the treatment of chronic obstructive pulmonary disease (COPD) through its flagship product, the Zephyr valve. The company is at the forefront of advancements in pulmonary health, aiming to capture a substantial market opportunity, particularly focusing on enhancing patient access to advanced therapies. Pulmonx is well-positioned to leverage emerging trends in lung health as healthcare priorities shift towards more proactive treatment options.

Bull says

  • ↑Maintains 2026 revenue guidance of $90–92M, targeting sequential quarterly improvement
  • ↑Aims for 70,000+ first-time patient engagements in 2025 via DTP campaigns
  • ↑CONVERT II pivotal trial due 2027 could expand addressable market ~20%
  • ↑Q1 cash stood at $61.6M; 10%+ operating cost reduction boosts leverage
  • ↑Gross margin at 78%; strong clinician relationships support revenue stability
  • ↑Positive earnings estimate revisions and robust fiscal stability signal upside

Bear says

  • ↓Q1 revenue down 9% YoY to $20.6M; U.S. fell 7%, international down 12%
  • ↓Earnings yield negative; profitability metrics underline weak return generation
  • ↓Elevated leverage and high short interest reflect investor skepticism
  • ↓Chinese registration renewal delay threatens $7.3M international revenue recovery
  • ↓High sales turnover and full sales team overhaul risk execution
  • ↓Rising competition from larger device firms pressures market share

Earnings Call · Q1 2025 · Mgmt. Guidance

Updated 05-30-2026neutral

Transcript signals

Bull points

  • I am pleased to report that Pomonix delivered worldwide sales of $22.5 million in the first quarter of 2025, representing 20% growth over the same period last year and 21% on a constant currency basis.
  • we remain confident in our ability to deliver on our previously communicated revenue guidance of $96 to $98 million for the full year 2025.
  • We expect the strong foundation we are building will help accelerate penetration into our estimated $12 billion market opportunity and support growth at or above 20% over the long term.

Bear points

  • While US growth has moderated over the past four quarters, it has sharpened our view of key pressure points in the patient funnel, and we're taking decisive action to unlock the next phase of expansion.
  • I think we're seeing a willingness of customers to adopt this technology to identify patients passively that are already in their system.
  • So I would say that the comp was probably what made the U.S. growth seem a little bit lower than expected.
Read full transcript analysis ›